Scailyte is a biotech company developing artificial intelligence (AI) technology for biomedical research, pharmaceutical discovery and precision diagnostics.
Scailyte's solution provides unprecedented insight into diseases by uncovering human's hidden "single-cell" secrets.
Scailyte was co-founded in 2017 by Peter Nestorov, Manfred Claassen, Dennis Göhlsdorf and Daniel Sonnleithner. The company is headquartered in Sursee, Lucerne, Switzerland.
Scailyte's mission is to develop the next generation diagnostics using single-cell analysis to save lives.
Scailyte discovers ultrasensitive biomarkers and develops in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™, which offers best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery and precision diagnostics.
Scailyte is also providing biomarker discovery service leveraging their expertise in single-cell technologies and AI-based data analytics solutions. The company supports pharmaceutical companies during the drug discovery & development process by introducing and implementing single-cell approaches for the discovery of novel disease mechanisms, as well as discovery of biomarkers for drug efficacy, toxicity and patient stratification.
Scailyte is backed by Swisscom Ventures, 4FO Ventures, HEMEX AG, Venture Kick and others. The company raised CHF 3.1M in a pre-Series A round on June 09, 2020. This brings Scailyte's total funding to CHF 6.7M to date.